New drug combo aims to fight tough stomach and esophageal cancers
NCT ID NCT07432295
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) will be randomly assigned to get the new combo or standard treatment alone. Participants receive infusions every 2-3 weeks and are monitored closely for side effects and tumor changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I-MAB Site 1005
RECRUITINGDuarte, California, 91010, United States
Contact
-
I-Mab Site - 4001
NOT_YET_RECRUITINGKashiwa, Japan
Contact
-
I-Mab Site 1002
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
I-Mab Site 1016
RECRUITINGGoodyear, Arizona, 85338, United States
Contact
-
I-Mab Site 2001
RECRUITINGBeijing, China
Contact
-
I-Mab Site 4005
RECRUITINGTokyo, Japan
Contact
Conditions
Explore the condition pages connected to this study.